Trastuzumab has had such a tremendous impact on the management of patients with HER2+ advanced [4] and early breast cancer [2, 5–7], leading to the development and increased use of other HER2-targeted therapies such as pertuzumab, another IgG1 HER2-specific monoclonal antibody [8]. Here, ERBB2 is linked to breast carcinoma.